Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROPACE, INC.

(NPCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeuroPace : Morgan Stanley Initiates NeuroPace at Overweight With $26 Price Target

05/17/2021 | 09:04am EST


© MT Newswires 2021
All news about NEUROPACE, INC.
11/11Wells Fargo Adjusts Price Target on NeuroPace to $20 From $28, Reiterates Overweight Ra..
MT
11/10NEUROPACE INC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10NeuroPace Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/10Earnings Flash (NPCE) NEUROPACE Reports Q3 Revenue $10.3M, vs. Street Est of $10.8M
MT
11/10NeuroPace Reports Third Quarter 2021 Financial Results
AQ
11/10Neuropace, Inc. Provides Revenue Guidance for the Full Year 2021
CI
11/10NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System fo..
AQ
11/10NeuroPace, Inc. Receives IDE Approval to Initiate Nautilus Pivotal Study of Its RNS Sys..
CI
10/20NEUROPACE : to Report Third Quarter 2021 Financial Results on November 10, 2021
GL
10/20NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021
GL
More news
Analyst Recommendations on NEUROPACE, INC.
More recommendations
Financials (USD)
Sales 2021 44,2 M - -
Net income 2021 -33,8 M - -
Net Debt 2021 3,00 M - -
P/E ratio 2021 -5,28x
Yield 2021 -
Capitalization 230 M 230 M -
EV / Sales 2021 5,28x
EV / Sales 2022 4,93x
Nbr of Employees 165
Free-Float 61,6%
Chart NEUROPACE, INC.
Duration : Period :
NeuroPace, Inc. Technical Analysis Chart | NPCE | US6412881053 | MarketScreener
Technical analysis trends NEUROPACE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,47 $
Average target price 22,80 $
Spread / Average Target 141%
EPS Revisions
Managers and Directors
Michael Favet President, Chief Executive Officer & Director
Rebecca L. Kuhn CFO, Vice President-Finance & Administration
Frank M. Fischer Chairman
Martha J. Morrell Chief Medical Officer
Cairn Seale Vice President-Clinical & Research
Sector and Competitors
1st jan.Capi. (M$)
NEUROPACE, INC.0.00%237
THERMO FISHER SCIENTIFIC33.59%245 196
DANAHER CORPORATION38.16%219 304
INTUITIVE SURGICAL, INC.17.94%115 663
SIEMENS HEALTHINEERS AG51.93%80 663
EDWARDS LIFESCIENCES CORPORATION20.38%69 900